In Segment A, members will obtain different doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. Additional individuals will be enrolled on the discovered monotherapy dosign regimen. In Section B, members will acquire oral ruxolitinib and ABBV-744 will likely be supplied as "add-on" therapy. In Segment C, https://abbv-744inthetreatmentofd69134.ziblogs.com/32163156/about-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers